Autres langues NetraMark Holdings Inc.

Actions

AIAI

CA64119M1059

Logiciels

Marché Fermé - Toronto S.E. 20:50:22 04/09/2026			Varia. 5j.	Varia. 1 janv.
0,6500 ^CAD	+1,56 %		-4,41 %	-40,91 %

01/09	Netramark Holdings Inc. annonce la nomination de Keith M. Fournier à son conseil d'administration	CI
14/08	NetraMark Holdings Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 juin 2026	CI

Autres langues

01/09	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors
01/09	NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
27/08	NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
20/08	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High
14/08	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
13/07	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
09/07	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data
09/07	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
25/05	Upcoming Meeting Dates - May 25, 2026
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
14/05	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026
14/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
07/05	NetraMark Announces Change To Board Of Directors
07/05	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
04/05	NetraMark Holdings Inc. Announces Executive Changes
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
22/04	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs